Novartis employs about 75.3 K people. The company is managed by 15 executives with a total tenure of roughly 175623 years, averaging almost 11708.0 years of service per executive, having 5017.8 employees per reported executive. Recap of Novartis' management performance can provide insight into the venture performance.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Novartis Management Team Effectiveness
The company has return on total asset (ROA) of 0.1114 % which means that it generated a profit of $0.1114 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3081 %, meaning that it generated $0.3081 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 0.33 in 2026, whereas Return On Tangible Assets are likely to drop 0.13 in 2026. At this time, Novartis' Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to climb to about 10.5 B in 2026, whereas Non Current Assets Total are likely to drop slightly above 74 B in 2026.
Novartis Quarterly Income Before Tax
3.24 Billion
Common Stock Shares Outstanding is likely to drop to about 1.9 B in 2026. Net Income Applicable To Common Shares is likely to drop to about 13.6 B in 2026Novartis AG maintains a total of 1.91 Billion outstanding shares. 30% of Novartis outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation
First Issued
2000-03-31
Previous Quarter
2 B
Current Value
1.9 B
Avarage Shares Outstanding
2.3 B
Quarterly Volatility
162.6 M
Dot-com Bubble
Housing Crash
Credit Downgrade
Yuan Drop
Covid
Interest Hikes
Some institutional investors establish a significant position in stocks such as Novartis in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Novartis, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Novartis AG is regarded third in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 212,250. Novartis totals roughly 75,267 in number of employees claiming about 35% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.25 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.28.
The output start index for this execution was zero with a total number of output elements of sixty-one. Novartis AG Price Series Summation is a cross summation of Novartis price series and its benchmark/peer.
Novartis Notable Stakeholders
A Novartis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novartis often face trade-offs trying to please all of them. Novartis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novartis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
The success or failure of an entity such as Novartis AG often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG. Check Novartis' Beneish M Score to see the likelihood of Novartis' management manipulating its earnings.
Novartis Workforce Analysis
Traditionally, organizations such as Novartis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novartis within its industry.
Novartis Manpower Efficiency
Return on Novartis Manpower
Revenue Per Employee
759K
Revenue Per Executive
3.8B
Net Income Per Employee
194.6K
Net Income Per Executive
976.6M
Working Capital Per Employee
42.3K
Working Capital Per Executive
212.1M
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.